TY - JOUR
T1 - Defects in pyrimidine degradation identified by HPLC-electrospray tandem mass spectrometry of urine specimens or urine-soaked filter paper strips
AU - Van Lenthe, H.
AU - Van Kuilenburg, A. B.P.
AU - Ito, T.
AU - Bootsma, A. H.
AU - Van Cruchten, A.
AU - Wada, Y.
AU - Van Gennip, A. H.
PY - 2000
Y1 - 2000
N2 - Background: Urinary concentrations of thymine, uracil, and their degradation products are useful indicators of deficiencies of enzymes of the pyrimidine degradation pathway. We describe a rapid, specific method to measure these concentrations to detect inborn errors of pyrimidine metabolism. Methods: We used urine or urine-soaked filter-paper strips as samples and measured thymine, uracil and their degradation products dihydrothymine, dihydrouracil, N-carbamyl-β-aminoisobutyric acid and N-carbamyl-β-alanine. Reversed-phase HPLC was combined with electrospray ionization tandem mass spectrometry, and detection was performed by multiple-reaction monitoring. Stable-isotope-labeled reference compounds were used as internal standards. Results: All pyrimidine degradation products could be measured in one analytical run of 15 min. Detection limits were 0.4-4 μmol/L. The intraassay imprecision (CV) of urine samples with added compounds was 1.3-12% for liquid urines and 1.0-10% for filter-paper extracts of the urines. The interassay imprecision (CV) was 3-11% (100-200 μmol/L). Recoveries were 89-99% at 100-200 μmol/L and 95-106% at 1 mmol/L in liquid urines and 93-103% at 100-200 μmol/L and 100-106% at 1 mmol/L in filter-paper samples. Correct identifications of deficiencies of the pyrimidine-degrading enzymes were readily made with urine samples from patients with known defects. Conclusions: HPLC with electrospray ionization tandem mass spectrometry allows rapid testing for disorders of the pyrimidine degradation pathway and filter-paper samples allow easy collection, transport and storage of urine samples. (C) 2000 American Association for Clinical Chemistry.
AB - Background: Urinary concentrations of thymine, uracil, and their degradation products are useful indicators of deficiencies of enzymes of the pyrimidine degradation pathway. We describe a rapid, specific method to measure these concentrations to detect inborn errors of pyrimidine metabolism. Methods: We used urine or urine-soaked filter-paper strips as samples and measured thymine, uracil and their degradation products dihydrothymine, dihydrouracil, N-carbamyl-β-aminoisobutyric acid and N-carbamyl-β-alanine. Reversed-phase HPLC was combined with electrospray ionization tandem mass spectrometry, and detection was performed by multiple-reaction monitoring. Stable-isotope-labeled reference compounds were used as internal standards. Results: All pyrimidine degradation products could be measured in one analytical run of 15 min. Detection limits were 0.4-4 μmol/L. The intraassay imprecision (CV) of urine samples with added compounds was 1.3-12% for liquid urines and 1.0-10% for filter-paper extracts of the urines. The interassay imprecision (CV) was 3-11% (100-200 μmol/L). Recoveries were 89-99% at 100-200 μmol/L and 95-106% at 1 mmol/L in liquid urines and 93-103% at 100-200 μmol/L and 100-106% at 1 mmol/L in filter-paper samples. Correct identifications of deficiencies of the pyrimidine-degrading enzymes were readily made with urine samples from patients with known defects. Conclusions: HPLC with electrospray ionization tandem mass spectrometry allows rapid testing for disorders of the pyrimidine degradation pathway and filter-paper samples allow easy collection, transport and storage of urine samples. (C) 2000 American Association for Clinical Chemistry.
UR - http://www.scopus.com/inward/record.url?scp=0033634995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033634995&partnerID=8YFLogxK
U2 - 10.1093/clinchem/46.12.1916
DO - 10.1093/clinchem/46.12.1916
M3 - Article
C2 - 11106323
AN - SCOPUS:0033634995
SN - 0009-9147
VL - 46
SP - 1916
EP - 1922
JO - Clinical Chemistry
JF - Clinical Chemistry
IS - 12
ER -